Laurence J. van Warmerdam

Author

Also Known As

L J van Warmerdam, L. J. Van Warmerdam, L.J. van Warmerdam, Laurence J van Warmerdam, Laurence J. van Warmerdam, Laurence JC van Warmerdam

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute VieCuri Medisch Centrum Ziekenhuis Groep Twente Canisius-Wilhelmina Ziekenhuis Reinier de Graaf Hospital

About

Laurence J. van Warmerdam is an author at The Netherlands Cancer Institute specializing in cancer therapeutics, pharmacotherapy, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	413
2	Pharmacology	1	1	413
3	Cancer Therapeutics	1	1	413
4	Breast Cancer	1	1	413
5	Oncology	1	1	413

Laurence J. van Warmerdam

Publications

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven, The Lancet Oncology Breast OncologyOncologyDual Her2 BlockadePharmacologyBreast Cancer	2018	413
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. Manon Huizing, Giuseppe Giaccone, Laurence J. van Warmerdam, Journal of Clinical Oncology	1997	181
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual<i>ERBB2</i>Blockade in Patients With<i>ERBB2</i>-Positive Breast Cancer Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven, JAMA Oncology	2021	130
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. Manon Huizing, Laurence J. van Warmerdam, Hilde Rosing, Journal of Clinical Oncology	1997	77
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. Laurence J. van Warmerdam, W.W. ten Bokkel Huinink, Sjoerd Rodenhuis, Journal of Clinical Oncology	1995	69
An overview of the clinical pharmacology of topotecan. Michael J. Dennis, Jos H. Beijnen, L B Grochow, PubMed	1997	57
Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia Maureen J.B. Aarts, Frank Peters, Caroline M.P.W. Mandigers, Journal of Clinical Oncology	2013	49
Cost Effectiveness of Primary Pegfilgrastim Prophylaxis in Patients With Breast Cancer at Risk of Febrile Neutropenia Maureen J.B. Aarts, Janneke P.C. Grutters, Frank Peters, Journal of Clinical Oncology	2013	42
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion Roel van Gljn, W.W. ten Bokkel Huinink, Sjoerd Rodenhuis, Anti-Cancer Drugs	1999	20

Page 1